Investment
Features
FeesSafety
Academy
More
Pluang+

BlackRock's DVY ETF outperformed PIMCO's PDI by nearly 100% over 10 years despite lower monthly payouts.

Market News
19 Oct 2026
24/7 Wall Street
View Source
Neutral
BlackRock's DVY ETF outperformed PIMCO's PDI by nearly 100% over 10 years despite lower monthly payouts.

Over the past decade, BlackRock's iShares Select Dividend ETF (DVY) returned 171.32%, significantly outperforming PIMCO's Dynamic Income Fund (PDI), which returned 77.64% with reinvested distributions. While PDI offers higher monthly income favored by retirees, its total return lags behind DVY, which invests in high-dividend U.S. stocks. The comparison highlights a trade-off between steady income and long-term growth, with DVY better suited for reinvestors and PDI for those needing regular cash flow. Investors should consider their income needs and tax implications when choosing between these funds.

This story compares BlackRock's DVY and PIMCO's PDI returns over ten years, with DVY achieving 171.32% versus PDI's 77.64%. For readers following US stocks on Pluang, here is the market snapshot as of Oct 20, 2026 07:01 WIB: out of 150 priced stocks, 60 rose and 90 fell. Notable movers include AMZN at USD 263.34 with a 1-day change of +5.34%, AGNC at USD 8.32 down -4.59%, and PLTR at USD 194.42 up +4.51%, with varied typical hold times and Pluang order activity percentages.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App